跳至主要内容
临床试验/NCT01879098
NCT01879098已完成1 期

Evaluation of the Effect of 3 Probiotic Strains on Bile Acids, Satiety, and Inflammation in Healthy, Middle-aged Adults: a Randomized, Double-blinded, Placebo-controlled Study

University of Florida1 个研究点 分布在 1 个国家目标入组 155 人开始时间: 2013年8月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
155
试验地点
1
主要终点
Difference in deconjugated bile acids in the blood

研究概览

简要总结

The purpose of this research study is to determine whether a probiotic can change the way bile is used by the body. The investigators will also look at the effect of the probiotic on your intestinal health.

详细描述

This is a randomized, double-blind, placebo controlled crossover study. After obtaining informed consent, healthy, middle-aged adults with a larger waist circumference (n=30/probiotic cross with n=90 total/study) will be randomized to one of four groups: Bacillus subtilis, Lactobacillus plantarum, Bifidobacterium animalis subsp. lactis, or placebo. Participants will consume 1 capsule per day of probiotic or placebo for 6 weeks. After a 4-week washout period, participants will be crossed to the other treatment (i.e., probiotic to placebo or placebo to probiotic).

Participants will complete daily questionnaires throughout the intervention period, and one week before and after each intervention period. Blood samples will be collected at the baseline and final time points (±3 days) of each intervention. Stool samples will be collected during the pre-baseline and final weeks of each intervention. Dietary intake will be assessed weekly during each intervention period. Gastrointestinal symptoms and physical activity questionnaires will be completed weekly during each intervention period and also the weeks before and after each intervention period.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
35 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •To participate in the study you must:
  • •Be 35-65 years of age.
  • •Have a waist circumference > 102 cm (40 in) for males, and > 88 cm (35 in) for females.
  • •Be willing and able to complete the Informed Consent Form in English.
  • •Be available for 18 consecutive weeks to participate in this study.
  • •Be willing and able to complete daily and weekly questionnaires regarding general wellness, bowel function, gastrointestinal symptoms, physical activity level, and dietary intake.
  • •Be willing to provide 4 blood samples and 4 stool samples.
  • •Be willing to maintain your regular level of physical activity and your diet for 18-week study.
  • •Be able to take the study supplement without the aid of another person.
  • •Be willing to discontinue consumption of fermented foods or probiotics (e.g., yogurts with live, active cultures or supplements).
  • •Be willing to provide a social security number (SS#) to receive study payment. Note: the subject can still participate if unwilling to provide SS#, but no financial reimbursement can be provided.

排除标准

  • •To participate in the study you must NOT:
  • •Fail to meet any of the criteria I mentioned above.
  • •Consume >20 g fiber daily, according to the Block Fiber Screener.
  • •Be taking any statins or cholesterol-lowering prescription drugs now, or within the last 6 months.
  • •Be currently taking any constipation or diarrhea on a regular basis.
  • •Be currently taking any systemic corticosteroids, androgens (such as testosterone), or large doses of anti-inflammatory drugs (i.e., aspirin in doses >600 mg/d) on a regular basis.
  • •Have used plant sterols, n-3 fatty acids, fish oil, soy protein, soluble oat fiber, psyllium seed husk or other cholesterol-lowering supplements within the last 3 months.
  • •Have received antibiotic therapy or a colonoscopy in the past two months.
  • •Currently be treated for or have any of the following physician-diagnosed diseases or conditions: HIV/AIDS; immune modulating diseases (autoimmune disease, hepatitis, cancer); kidney disease; pancreatitis; pulmonary disease; hepatic or biliary disease; or gastrointestinal diseases/conditions such as diverticulitis, ulcerative colitis, Crohn's disease, Celiac disease, short bowel disease, ileostomy, colostomy, but not including Gastroesophageal Reflux Disease (GERD); or have a central venous catheter.
  • •Taking medications for type 1 or type 2 diabetes.
  • •Be physically active or very physically active. Active = typical daily living activities PLUS at least 60 minutes of daily moderate activity. Very active = typical daily living activities PLUS at least 60 minutes of daily moderate activity, PLUS an additional 60 minutes of vigorous activity OR 120 minutes of moderate activity.

研究组 & 干预措施

Placebo

Placebo Comparator

Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).

干预措施: Placebo (Dietary Supplement)

Probiotic: Bacillus subtilis

Experimental

Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).

干预措施: Probiotic: Bacillus subtilis (Dietary Supplement)

Probiotic: Bifidobacterium animalis

Experimental

Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).

干预措施: Bifidobacterium animalis (Dietary Supplement)

Probiotic: Lactobacillus plantarum

Experimental

Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).

干预措施: Lactobacillus plantarum (Dietary Supplement)

结局指标

主要结局

Difference in deconjugated bile acids in the blood

时间窗: Baseline #1 (Week 1) to Week 8 and Baseline #2 (Week 11) to Week 18

Levels of deconjugated bile acids in the stool and in the blood will be compared between treatment periods for each subject/group.

次要结局

  • Satiety and glucose metabolism(Baseline #1 (Week 1) to Week 8 and Baseline #2 (Week 11) to Week 18)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验